Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Austin, TX, USA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Adeno Associated Virus Vector Manufacturing Market Size, Trends and Insights By ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

A new review tracks expanding chikungunya transmission, chronic sequelae, diagnostics, and prevention advances through 2025.